Literature DB >> 29632194

In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis.

Qibiao Wu1, Yahui Tian2, Jian Zhang1, Xinyuan Tong1, Hsinyi Huang1, Shuai Li3, Hong Zhao2, Ying Tang1, Chongze Yuan4,5, Kun Wang6, Zhaoyuan Fang1, Lei Gao2, Xin Hu7,8, Fuming Li1, Zhen Qin1, Shun Yao1, Ting Chen3, Haiquan Chen4,5, Gong Zhang2, Wanting Liu2, Yihua Sun4,5, Luonan Chen1, Kwok-Kin Wong3, Kai Ge9, Liang Chen10, Hongbin Ji11,12.   

Abstract

Lung cancer is the leading cause of cancer-related death worldwide. Inactivation of tumor suppressor genes (TSGs) promotes lung cancer malignant progression. Here, we take advantage of the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated somatic gene knockout in a KrasG12D/+ mouse model to identify bona fide TSGs. From individual knockout of 55 potential TSGs, we identify five genes, including Utx, Ptip, Acp5, Acacb, and Clu, whose knockout significantly promotes lung tumorigenesis. These candidate genes are frequently down-regulated in human lung cancer specimens and significantly associated with survival in patients with lung cancer. Through crossing the conditional Utx knockout allele to the KrasG12D/+ mouse model, we further find that Utx deletion dramatically promotes lung cancer progression. The tumor-promotive effect of Utx knockout in vivo is mainly mediated through an increase of the EZH2 level, which up-regulates the H3K27me3 level. Moreover, the Utx-knockout lung tumors are preferentially sensitive to EZH2 inhibitor treatment. Collectively, our study provides a systematic screening of TSGs in vivo and identifies UTX as an important epigenetic regulator in lung tumorigenesis.

Entities:  

Keywords:  CRISPR/Cas9 in vivo knockout; EZH2 inhibitor; UTX; non-small cell lung cancer; tumor suppressor genes

Mesh:

Substances:

Year:  2018        PMID: 29632194      PMCID: PMC5924887          DOI: 10.1073/pnas.1716589115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex.

Authors:  Young-Wook Cho; Teresa Hong; Sunhwa Hong; Hong Guo; Hong Yu; Doyeob Kim; Tad Guszczynski; Gregory R Dressler; Terry D Copeland; Markus Kalkum; Kai Ge
Journal:  J Biol Chem       Date:  2007-05-11       Impact factor: 5.157

Review 2.  Transcriptional regulation by Polycomb group proteins.

Authors:  Luciano Di Croce; Kristian Helin
Journal:  Nat Struct Mol Biol       Date:  2013-10       Impact factor: 15.369

3.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

4.  A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

Authors:  Helai P Mohammad; Kimberly N Smitheman; Chandrashekhar D Kamat; David Soong; Kelly E Federowicz; Glenn S Van Aller; Jess L Schneck; Jeffrey D Carson; Yan Liu; Michael Butticello; William G Bonnette; Shelby A Gorman; Yan Degenhardt; Yuchen Bai; Michael T McCabe; Melissa B Pappalardi; Jiri Kasparec; Xinrong Tian; Kenneth C McNulty; Meagan Rouse; Patrick McDevitt; Thau Ho; Michelle Crouthamel; Timothy K Hart; Nestor O Concha; Charles F McHugh; William H Miller; Dashyant Dhanak; Peter J Tummino; Christopher L Carpenter; Neil W Johnson; Christine L Hann; Ryan G Kruger
Journal:  Cancer Cell       Date:  2015-07-13       Impact factor: 31.743

5.  UTX regulates mesoderm differentiation of embryonic stem cells independent of H3K27 demethylase activity.

Authors:  Chaochen Wang; Ji-Eun Lee; Young-Wook Cho; Ying Xiao; Qihuang Jin; Chengyu Liu; Kai Ge
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

6.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

7.  The histone demethylase UTX enables RB-dependent cell fate control.

Authors:  Jordon K Wang; Miao-Chih Tsai; Gino Poulin; Adam S Adler; Shuzhen Chen; Helen Liu; Yang Shi; Howard Y Chang
Journal:  Genes Dev       Date:  2010-02-01       Impact factor: 11.361

8.  Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases.

Authors:  Sunhwa Hong; Young-Wook Cho; Li-Rong Yu; Hong Yu; Timothy D Veenstra; Kai Ge
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-14       Impact factor: 11.205

9.  Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors:  Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

10.  Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.

Authors:  Gijs van Haaften; Gillian L Dalgliesh; Helen Davies; Lina Chen; Graham Bignell; Chris Greenman; Sarah Edkins; Claire Hardy; Sarah O'Meara; Jon Teague; Adam Butler; Jonathan Hinton; Calli Latimer; Jenny Andrews; Syd Barthorpe; Dave Beare; Gemma Buck; Peter J Campbell; Jennifer Cole; Simon Forbes; Mingming Jia; David Jones; Chai Yin Kok; Catherine Leroy; Meng-Lay Lin; David J McBride; Mark Maddison; Simon Maquire; Kirsten McLay; Andrew Menzies; Tatiana Mironenko; Lee Mulderrig; Laura Mudie; Erin Pleasance; Rebecca Shepherd; Raffaella Smith; Lucy Stebbings; Philip Stephens; Gurpreet Tang; Patrick S Tarpey; Rachel Turner; Kelly Turrell; Jennifer Varian; Sofie West; Sara Widaa; Paul Wray; V Peter Collins; Koichi Ichimura; Simon Law; John Wong; Siu Tsan Yuen; Suet Yi Leung; Giovanni Tonon; Ronald A DePinho; Yu-Tzu Tai; Kenneth C Anderson; Richard J Kahnoski; Aaron Massie; Sok Kean Khoo; Bin Tean Teh; Michael R Stratton; P Andrew Futreal
Journal:  Nat Genet       Date:  2009-03-29       Impact factor: 38.330

View more
  31 in total

Review 1.  Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Cancers (Basel)       Date:  2018-07-27       Impact factor: 6.639

Review 2.  UTX Mutations in Human Cancer.

Authors:  Lu Wang; Ali Shilatifard
Journal:  Cancer Cell       Date:  2019-02-11       Impact factor: 31.743

3.  IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function.

Authors:  Jinxia Liang; Feng Lu; Bo Li; Lu Liu; Guandi Zeng; Qian Zhou; Liang Chen
Journal:  Cell Cycle       Date:  2019-10-09       Impact factor: 4.534

Review 4.  Tutorial: design and execution of CRISPR in vivo screens.

Authors:  Christian J Braun; Andrés Carbonell Adames; Dieter Saur; Roland Rad
Journal:  Nat Protoc       Date:  2022-07-15       Impact factor: 17.021

Review 5.  The role and function of CLU in cancer biology and therapy.

Authors:  Yefei Zhang; Xiang Lv; Liming Chen; Yan Liu
Journal:  Clin Exp Med       Date:  2022-09-13       Impact factor: 5.057

6.  Epigenetic and metabolic interplay in cutaneous squamous cell carcinoma.

Authors:  Gina Pacella; Brian C Capell
Journal:  Exp Dermatol       Date:  2021-04-22       Impact factor: 3.960

7.  Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma.

Authors:  Jiaqing Yi; Xuanming Shi; Zhenyu Xuan; Jiang Wu
Journal:  Cancer Lett       Date:  2020-11-27       Impact factor: 8.679

8.  Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer.

Authors:  Qian Zhou; Wensheng Chen; Zhenzhen Fan; Zhipeng Chen; Jinxia Liang; Guandi Zeng; Lu Liu; Wanting Liu; Tong Yang; Xin Cao; Biao Yu; Meng Xu; Ye-Guang Chen; Liang Chen
Journal:  Theranostics       Date:  2021-05-03       Impact factor: 11.556

9.  A systematic dissection of the epigenomic heterogeneity of lung adenocarcinoma reveals two different subclasses with distinct prognosis and core regulatory networks.

Authors:  Chongze Yuan; Haojie Chen; Shiqi Tu; Hsin-Yi Huang; Yunjian Pan; Xiuqi Gui; Muyu Kuang; Xuxia Shen; Qiang Zheng; Yang Zhang; Chao Cheng; Hui Hong; Xiaoting Tao; Yizhou Peng; Xingxin Yao; Feilong Meng; Hongbin Ji; Zhen Shao; Yihua Sun
Journal:  Genome Biol       Date:  2021-05-17       Impact factor: 13.583

Review 10.  CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries.

Authors:  K Sreedurgalakshmi; R Srikar; Reena Rajkumari
Journal:  Cancer Gene Ther       Date:  2020-11-15       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.